【0】Fezolinetant: Drug information

【1】Contributor Disclosures

【2】For abbreviations, symbols, and age group definitions show table

【3】Brand Names: US

【4】*   Veozah

【5】Pharmacologic Category

【6】*   Neurokinin 3 Receptor Antagonist

【7】Dosing: Adult

【8】**Note:** Perform LFTs prior to initiation; do not initiate therapy in patients with ALT, AST, and/or total bilirubin ≥2 times the ULN.

【9】Vasomotor symptoms associated with menopause

【10】**Vasomotor symptoms associated with menopause: Oral:** 45 mg once daily.

【11】_Missed doses:_ If a dose is missed, administer the dose as soon as remembered; if there is <12 hours before the next scheduled dose, skip the missed dose and return to the regular schedule the following day.

【12】Dosing: Kidney Impairment: Adult

【13】GFR ≥30 mL/minute/1.73 m 2 : No dosage adjustment necessary.

【14】GFR <30 mL/minute/1.73 m 2 : Use is contraindicated.

【15】Dosing: Hepatic Impairment: Adult

【16】Hepatic impairment prior to treatment initiation:

【17】Mild to moderate impairment (Child-Pugh class A or B): Use is contraindicated; increased exposure of fezolinetant has been reported.

【18】Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied).

【19】ALT, AST, and/or total bilirubin ≥2 times the ULN: Withhold treatment.

【20】Hepatotoxicity during treatment:

【21】ALT, AST, and/or total bilirubin ≥2 times the ULN: Withhold treatment.

【22】Dosing: Older Adult

【23】Refer to adult dosing.

【24】Adverse Reactions

【25】The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

【26】1% to 10%:

【27】Endocrine & metabolic: Hot flash 

【28】Gastrointestinal: Abdominal pain , diarrhea 

【29】Hepatic: Increased serum transaminases 

【30】Nervous system: Insomnia 

【31】Neuromuscular & skeletal: Back pain 

【32】Contraindications

【33】Known cirrhosis; severe renal impairment or end-stage renal disease; concomitant use with CYP1A2 inhibitors.

【34】Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

【35】Warnings/Precautions

【36】_**Concerns related to adverse effects:**_

【37】• Hepatic transaminase elevation: Hepatic serum transaminase elevations (ie, ALT and AST) >3 times the ULN have occurred. Elevations are typically asymptomatic and resolve with continued therapy, dose interruption, or discontinuation.

【38】Dosage Forms: US

【39】Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

【40】Tablet, Oral:

【41】Veozah: 45 mg

【42】Generic Equivalent Available: US

【43】No

【44】Pricing: US

【45】**Tablets** (Veozah Oral)

【46】45 mg (per each): $22.00

【47】**Disclaimer:** A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

【48】Administration: Adult

【49】**Oral:** Administer at about the same time each day with liquids; administer with or without food. Swallow tablet whole; do not cut, crush, or chew.

【50】Use: Labeled Indications

【51】**Vasomotor symptoms** **associated with menopause:** Treatment of moderate to severe vasomotor symptoms due to menopause.

【52】Metabolism/Transport Effects

【53】**Substrate** of CYP1A2 (major), CYP2C19 (minor), CYP2C9 (minor), P-glycoprotein/ABCB1 (minor); **Note:** Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

【54】Drug Interactions  

【55】**Note** : Interacting drugs may **not be individually listed below** if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers \[Strong\]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

【56】Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【57】CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Fezolinetant. _Risk X: Avoid combination_

【58】CYP1A2 Inhibitors (Strong): May increase the serum concentration of Fezolinetant. _Risk X: Avoid combination_

【59】CYP1A2 Inhibitors (Weak): May increase the serum concentration of Fezolinetant. _Risk X: Avoid combination_

【60】Dinutuximab Beta: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【61】Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【62】Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【63】Filgotinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【64】Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【65】Leniolisib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk X: Avoid combination_

【66】Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【67】Pacritinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk X: Avoid combination_

【68】Ritlecitinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【69】Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【70】Tarlatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【71】Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). _Risk C: Monitor therapy_

【72】Pregnancy Considerations

【73】Fezolinetant is approved for moderate to severe vasomotor symptoms in postmenopausal patients.

【74】Breastfeeding Considerations

【75】It is not known if fezolinetant is present in breast milk.

【76】Monitoring Parameters

【77】LFTs (including ALT, AST, total and direct serum bilirubin) prior to initiation of therapy; after initiation of therapy at 3, 6, and 9 months; and when symptoms suggest liver injury (eg, nausea, vomiting, yellowing of the skin or eyes).

【78】Mechanism of Action

【79】Neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center.

【80】Pharmacokinetics (Adult Data Unless Noted)

【81】Distribution: V z /F: 189 L.

【82】Protein binding: 51%.

【83】Metabolism: Primarily by CYP1A2; CYP2C9 and CYP2C19 to a lesser extent.

【84】Half-life elimination: 9.6 hours.

【85】Time to peak: Median 1.5  hours.

【86】Excretion: Urine: 76.9% ; feces: 14.7% .

【87】Clearance: 10.8 L/hour.黄艳玲

====================================================================================================
